GlaxoSmithKline (GSK) in July made its consumer health products division a separate entity as it transforms into a world-leading biopharmaceutical company. By uniting science, technology and talent, the company is aiming to prevent and treat diseases with innovative vaccines, specialty pharmaceuticals and general medicines.
GSK’s headquarters annually invests NT$192 billion (US$6.07 billion) in research and development, focusing on immune science and advanced technologies in human genetics. GSK’s drug and vaccine development focuses on infectious diseases, HIV, oncology and immunology.
Investing in clinical trial research each year, GSK also brings drug development to Taiwan. It cooperates with 17 medical institutes and research centers in Taiwan to help domestic medical research keep pace with international trends and enhance Taiwan’s status as a center for clinical research in the Asia-Pacific region.
Photo courtesy of GSK Taiwan
GSK has launched a revamped brand identity system, which was modified from its former orange logo consisting of lowercase “gsk” and a beating heart. The new logo adopts gradient orange, capitalized “GSK,” and digital and technological lines. Its design brings out a striking, eye-catching image, while conveying GSK’s goals and ideas for the future.
The arrow in the new logo symbolizes GSK’s combination of digital, social and environmental concerns as a “signal to move ahead together” in the biopharmaceutical industry. The curve in the logo symbolizes the ability of the immune system to adapt to and evolve along with the environment.
GSK’s Taiwan branch was established 43 years ago, and has since protected the health of Taiwanese.
“After transforming the organization, our new ambitions and new purpose is to expand our impact here in Taiwan by protecting and treating more patients, to make GSK a place where people can thrive, where they can succeed, grow and be happy at work, all underpinned by doing everything with integrity and care,” GSK Taiwan vice president and general manager Mick Stanley said.
The newly transformed GSK is focusing on protecting the health of Taiwanese with pharmaceuticals and vaccines, advocating and practicing the values of diversity and inclusion, and caring for employees and practicing sustainable development, all of which form the company’s business philosophy.
Being “ambitious for patients” is part of the corporate culture, which GSK attaches great importance to.
“In addition to ‘ambitious for patients,’ GSK’s culture also emphasizes ‘accountable for impact.’ We hope to expand our impacts on Taiwanese people,” Stanley said. “We hope we can move ahead together to defeat disease with medicines and vaccines.”
GSK provides as many as 50 kinds of prescription medicines and more than 15 kinds of vaccines, for children and adults, and endeavors to do its utmost for the health of Taiwanese.
Every day, 2 million doses of vaccines produced by GSK are administered around the world. In the past few years, GSK has advocated for adult vaccination. For example, GSK Taiwan has recently launched a new vaccine against the herpes zoster virus to protect against shingles.
To help Taiwanese become aware of the necessity of adult vaccination, GSK is working with entities in Taiwan to create and promote comprehensive information and an environment for adult vaccination.
GSK provides vaccines for infectious diseases that could occur at every stage of life. It helps provide proper immune protection against meningitis, quadrivalent influenza, polio, measles and other diseases. In Taiwan, an average of 40 percent of children receive vaccines provided by GSK.
GSK is also concerned about the healthcare challenges faced by Taiwan’s rapidly aging population. Accordingly, GSK has been discussing important policy developments with the government through the American Chamber of Commerce in Taiwan, the European Chamber of Commerce Taiwan and the International Research-Based Pharmaceutical Manufacturers Association, with the aim of helping Taiwan lay a solid foundation for its medical environment in the decades to come.
Additionally, since the invention of the first-ever medicine for the treatment of HIV, GSK has continuously worked to improve the health and quality of life of people living with HIV, and has cooperated with government entities and patient groups.
In addition to vaccines, GSK also leads the industry in the treatment and prevention of diseases such as respiratory illnesses. For people with asthma, chronic obstructive pulmonary disease and other respiratory diseases who need drugs for treatment, GSK helps them with a variety of inhaled medicines.
The world’s first inhaler was developed by GSK.
The company helps more than 2 million people with respiratory diseases every year in Taiwan, and allows them to breathe freely with improved quality of life.
Two US Federal Reserve officials reinforced expectations the central bank would slow their pace of interest rate increases next month, even as they stressed the need to keep tightening. San Francisco Fed President Mary Daly and Cleveland Fed President Loretta Mester said during separate remarks on Monday that inflation remains too high and policymakers have a way to go before completing their tightening campaign. However, they both characterized the need for officials to be judicious as they calibrate policy. “I think we can slow down from the 75 at the next meeting, I don’t have a problem with that,” Mester said during
‘SEASONED’: Chiang Shang-yi is to help guide Hon Hai’s global semiconductor development strategy as the firm accelerates the pace of capacity deployment Hon Hai Technology Group (鴻海科技集團) has hired former Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) cochief operating officer Chiang Shang-yi (蔣尚義) as a strategy officer to assist its semiconductor business development, the group said yesterday. Chiang’s appointment took effect immediately. He is to report directly to Hon Hai chairman Young Liu (劉揚偉). Chiang was the central figure in TSMC’s technology advancement, and once considered a potential successor to TSMC founder and former chairman Morris Chang (張忠謀). He spent the past few years in China assisting Chinese chipmakers Semiconductor Manufacturing International Corp (中芯國際) and Wuhan Hongxin Semiconductor Corp (武漢弘芯半導體). Chiang on Oct. 18 attended a
PRIORITY SHIFT: TSMC previously said it would build two new fabs in Kaohsiung, but earlier this month said it was postponing construction of a 7-nanometer factory Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) yesterday said that construction of a factory in Kaohsiung to produce 28-nanometer chips is under way, with mass production set to start in 2024. TSMC, the world’s largest contract chipmaker, made the announcement after reports about the company’s capacity expansion plans in Kaohsiung. Industry insiders said that TSMC on Friday awarded the contract to build the new fab to Fu Tsu Construction Co (互助營造). The chipmaker, a major Apple Inc supplier, did not directly respond to the reports, saying only that construction had started following the completion of land grading. TSMC previously said it intended to build a
More than 20,000 employees at Apple Inc supplier Foxconn Technology Group’s (富士康) huge Chinese plant, mostly new hires not yet working on production lines, have left, a Foxconn source familiar with the matter said yesterday. The departures from the world’s largest iPhone factory dealt a fresh blow to the Taiwanese company, which has been grappling with strict COVID-19 restrictions that have fueled worker discontent and disrupted production ahead of Christmas and January’s Lunar New Year holiday. Concerns are mounting over Apple’s ability to deliver products for the busy holiday period as the worker unrest lingers at the Zhengzhou plant, which produces the